Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins

Apoptosis

Volumn 18, Issue 5, 2013, Pages 618-626

  Yang, Lan ^a,b   Wang, Qiong ^a   Li, Daoxia ^a   Zhou, Yuqiong ^a   Zheng, Xuelian ^a   Sun, Hong ^a   Yan, Jiaqi ^a   Zhang, Lin ^a   Lin, Yong ^a   Wang, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Antitumor activity; Apoptosis; Cancer xenograft; TRAIL; Wogonin

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTYLATED HYDROXYANISOLE; FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LACTATE DEHYDROGENASE; PROTEASOME; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WOGONIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; IN VITRO STUDY; IN VIVO STUDY; LUNG SMALL CELL CANCER; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DRUG SYNERGISM; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

MUS MUSCULUS; SCUTELLARIA BAICALENSIS;

EID: 84876053101     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0808-8     Document Type: Article

References (27)

1. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
3. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-620
4. Wang X (2001) The expanding role of mitochondria in apoptosis. Genes Dev 15:2922-2933
5. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367
6. van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB et al (2002) Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62:2157-2161
7. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020-25025
8. Aggarwal BB, Bhardwaj U, Takada Y (2004) Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 67:453-483
9. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM et al (2010) A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 103:1783-1787
10. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13:6187-6194
11. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR et al (2000) Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19:4604-4610
12. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237
13. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA et al (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7:1156-1163
14. Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Kohler R et al (2011) Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis 2:e182
15. Chung H, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ et al (2008) Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int J Cancer 122:816-822
16. Fas SC, Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U et al (2006) Wogonin sensitizes resistant malignant cells to TNF alpha- and TRAIL-induced apoptosis. Blood 108:3700-3706
17. Lee DH, Rhee JG, Lee YJ (2009) Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol 157:1189-1202
18. Ding J, Polier G, Kohler R, Giaisi M, Krammer PH, Li-Weber M (2012) Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem 287:641-649
19. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734-741
20. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y (2007) A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappa B pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71:1381-1388
21. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y et al (2003) NF-kappa B inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22:3898-3909
22. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y (2006) 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappa B pathway. Cancer Res 66:1089-1095
23. Yang L, Zheng XL, Sun H, Zhong YJ, Wang Q, He HN et al (2011) Catalase suppression-mediated H(2)O(2) accumulation in cancer cells by wogonin effectively blocks tumor necrosis factor-induced NF-kappa B activation and sensitizes apoptosis. Cancer Sci 102:870-876
24. Ishibashi M, Ohtsuki T (2008) Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis. Med Res Rev 28:688-714
25. Shankar S, Siddiqui I, Srivastava RK (2007) Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 304:273-285
26. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M et al (2008) Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68:8918-8927
27. Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH et al (2008) The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 180:3072-3080